Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Supernus Pharm (NQ: SUPN ) 26.61 -0.47 (-1.74%) Streaming Delayed Price Updated: 12:57 PM EDT, Jun 13, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Supernus Pharm < Previous 1 2 Next > Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference May 30, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy May 23, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures May 09, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Announces First Quarter 2024 Financial Results May 08, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors May 02, 2024 From Glancy Prongay & Murray LLP Via Business Wire INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors May 01, 2024 From Law Offices of Howard G. Smith Via Business Wire Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story May 01, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors April 29, 2024 From The Law Offices of Frank R. Cruz Via Business Wire Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 April 24, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Provides Regulatory Update for SPN-830 April 08, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus to Participate in Two Upcoming Investor Conferences March 06, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference February 28, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Announces Fourth Quarter and Full Year 2023 Financial Results February 27, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024 February 13, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent February 05, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Announces Third Quarter 2023 Financial Results November 08, 2023 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus to Participate in the Jefferies London Healthcare Conference November 07, 2023 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA November 02, 2023 PDUFA Target Action Date of April 5, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023 October 25, 2023 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey October 16, 2023 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device October 09, 2023 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City September 27, 2023 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms September 09, 2023 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus to Participate in the Wells Fargo Healthcare Conference August 31, 2023 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Bethany L. Sensenig Joins Supernus’ Board of Directors August 21, 2023 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Announces Second Quarter 2023 Financial Results August 08, 2023 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 8, 2023 July 24, 2023 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus to Participate in the Jefferies Healthcare Conference May 31, 2023 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Announces First Quarter 2023 Financial Results May 09, 2023 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus to Present at the Bank of America 2023 Health Care Conference May 02, 2023 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.